{"title":"Leksell Radiosurgery for Ependymomas and Oligodendrogliomas.","authors":"Hideyuki Kano, L Dade Lunsford","doi":"10.1159/000493065","DOIUrl":null,"url":null,"abstract":"<p><p>Stereotactic radiosurgery (SRS) has become a standard management option for less common glial tumors. When imaging defines a recurrent or progressive ependymoma after initial resection in a child who has completed adjuvant fractionated radiation therapy, SRS may be used as a boost or salvage strategy. For patients with oligodendrogliomas diagnosed by biopsy or after cytoreductive surgery, SRS may be used as a primary option in smaller volume tumors, or as an adjuvant option for tumors that have progressed after initial surgery, chemotherapy, or fractionated radiation therapy. Currently the increasing use of molecular markers in both tumors helps to define the prognosis, risk of recurrence, and perhaps response to boost or salvage SRS. This report examines the role of SRS in these less common glial tumors.</p>","PeriodicalId":39342,"journal":{"name":"Progress in neurological surgery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000493065","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in neurological surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000493065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/5/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2
Abstract
Stereotactic radiosurgery (SRS) has become a standard management option for less common glial tumors. When imaging defines a recurrent or progressive ependymoma after initial resection in a child who has completed adjuvant fractionated radiation therapy, SRS may be used as a boost or salvage strategy. For patients with oligodendrogliomas diagnosed by biopsy or after cytoreductive surgery, SRS may be used as a primary option in smaller volume tumors, or as an adjuvant option for tumors that have progressed after initial surgery, chemotherapy, or fractionated radiation therapy. Currently the increasing use of molecular markers in both tumors helps to define the prognosis, risk of recurrence, and perhaps response to boost or salvage SRS. This report examines the role of SRS in these less common glial tumors.
期刊介绍：
Published since 1966, this series has become universally recognized as the most significant group of books serving neurological surgeons. Volumes feature contributions from distinguished international surgeons, who brilliantly review the literature from the perspective of their own personal experience. The result is a series of works providing critical distillations of developments of central importance to the theory and practice of neurological surgery.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
